The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
“A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment ...
The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...
She noted that a new non-opioid therapeutic class for acute pain can help reduce certain risks associated with using opioids for pain management and provides patients with an additional treatment ...
The first new class of non-opioid painkillers in more than two decades was approved by the Food and Drug Administration, the agency said Thursday. Suzetrigine, branded as Journavx, can be taken ...
What's more, the new painkiller doesn't include opioids like many painkillers currently on the market do. The FDA announced Thursday (Jan. 30) that it had approved the new class of prescription ...
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...